Top

Published in:

01-11-2013 | Leading Article

Breath Tests to Phenotype Drug Disposition in Oncology

Authors: Frans L. Opdam, Anil S. Modak, Hans Gelderblom, Henk-Jan Guchelaar

Published in: Clinical Pharmacokinetics | Issue 11/2013

Abstract

Breath tests (BTs) have been investigated as diagnostic tools to phenotype drug disposition in cancer patients in the pursuit to individualize drug treatment. The choice of the right phenotype probe is crucial and depends on the metabolic pathway of the anticancer agent of interest. BTs using orally or intravenously administered selective non-radioactive ¹³C-labeled probes to non-invasively evaluate dihydropyrimidine dehydrogenase, cytochrome P450 (CYP) 3A4, and CYP2D6 enzyme activity have been published. Clinically, a ¹³C-dextromethorphan BT to predict endoxifen levels in breast cancer patients and a ¹³C-uracil BT to predict fluoropyrimidine toxicity in colorectal cancer patients are most promising. However, the clinical benefit and cost effectiveness of these phenotype BTs need to be determined in order to make the transition from an experimental setting to clinical practice as companion diagnostic tests.

Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas–liquid partition chromatography. Proc Natl Acad Sci USA. 1971;68:2374–6.PubMedCrossRef

Afolabi P, Wright M, Wootton SA, Jackson AA. Clinical utility of C-13-liver-function breath tests for assessment of hepatic function. Dig Dis Sci. 2013;58:33–41.PubMedCrossRef

Minh TDC, Blake DR, Galassetti PR. The clinical potential of exhaled breath analysis for diabetes mellitus. Diabetes Res Clin Pract. 2012;97:195–205.CrossRef

Paschke KM, Mashir A, Dweik RA. Clinical applications of breath testing. F1000 Med Rep. 2010;2:56.PubMed

Chapman EA, Thomas PS, Yates DH. Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res. 2010;4:034001.PubMedCrossRef

Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008;84:287–94.PubMedCrossRef

Opdam FL, Gelderblom H, Guchelaar HJ. Phenotyping drug disposition in oncology. Cancer Treat Rev. 2012;38:715–25.PubMedCrossRef

Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther. 2007;81:270–83.PubMedCrossRef

de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol. 2011;29:3240–6.PubMedCrossRef

10.

Perera V, Gross AS, McLachlan AJ. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed Chromatogr. 2010;24:1136–44.PubMedCrossRef

11.

Petsalo A, Turpeinen M, Pelkonen O, Tolonen A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 micron particle size column. J Chromatogr A. 2008;1215:107–15.PubMedCrossRef

12.

Modak A. Diagnostic breath tests in personalized medicine. Expert Rev Mol Diagn. 2008;8:563–4.PubMedCrossRef

13.

Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Evaluation of a [(13)C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol. 2008;48:1041–51.PubMedCrossRef

14.

Modak AS. Stable isotope breath tests in clinical medicine: a review. J Breath Res. 2007;1:014003.PubMedCrossRef

15.

Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest. 1989;83:688–97.PubMedCrossRef

16.

Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4:171–84.PubMedCrossRef

17.

Schmidt LE, Olsen AK, Stentoft K, Rasmussen A, Kirkegaard P, Dalhoff K. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients. Clin Pharmacol Ther. 2001;70:446–54.PubMed

18.

Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992;51:229–38.PubMedCrossRef

19.

Kurnik D, Wood AJJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther. 2006;80:228–34.PubMedCrossRef

20.

Lan LB, Dalton JT, Schuetz EG. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol. 2000;58:863–9.PubMed

21.

Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther. 2008;84:704–9.PubMedCrossRef

22.

Franke RM, Baker SD, Schuetz EG, Sparreboom A. ABCC2 polymorphism as a determinant of the erythromycin breath test. Clin Pharmacol Ther. 2009;85:S67.

23.

Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 1990;38:207–13.PubMed

24.

Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187–216.PubMedCrossRef

25.

Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res. 2000;6:3480–5.PubMed

26.

Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology. 1994;20:309–16.PubMedCrossRef

27.

Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther. 1992;52:471–8.PubMedCrossRef

28.

Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther. 1990;48:120–9.PubMedCrossRef

29.

Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther. 1995;57:16–24.PubMedCrossRef

30.

Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther. 2004;76:341–9.PubMedCrossRef

31.

Kinirons MT, O’Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther. 1999;66:224–31.PubMedCrossRef

32.

Krivoruk Y, Kinirons MT, Wood AJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther. 1994;56:608–14.PubMedCrossRef

33.

Kinirons MT, Krivoruk Y, Wilkinson GR, Wood AJ. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. Br J Clin Pharmacol. 1999;47:223–5.PubMed

34.

Gharaibeh MN, Gillen LP, Osborne B, Schwartz JI, Waldman SA. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers. J Clin Pharmacol. 1998;38:492–5.PubMedCrossRef

35.

Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000;6:1255–8.PubMed

36.

Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res. 2006;12:6100–5.PubMedCrossRef

37.

Slaviero KA, Clarke SJ, McLachlan AJ, Blair EYL, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol. 2004;57:44–53.PubMedCrossRef

38.

Michael M, Cullinane C, Hatzimihalis A, O’Kane C, Milner A, Booth R, et al. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer Chemother Pharmacol. 2012;69:125–35.PubMedCrossRef

39.

Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther. 1992;52:265–73.PubMedCrossRef

40.

Hooker AC, Ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer E, Gelderblom H, et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements. Clin Pharmacol Ther. 2008;84:111–8.PubMedCrossRef

41.

Sparreboom A, Huizing MT, Boesenwillem JJB, Nooijen WJ, Vantellingen O, Beijnen JH. Isolation, purification, and biological-activity of monohydroxylated and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol. 1995;36:299–304.PubMedCrossRef

42.

Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, et al. Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br J Clin Pharmacol. 2012;74:197–200.PubMedCrossRef

43.

Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol. 2006;58:129–35.PubMedCrossRef

44.

Chugh R, Wagner T, Griffith KA, Taylor JM, Thomas DG, Worden FP, et al. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. Cancer. 2007;109:2315–22.PubMedCrossRef

45.

Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004;96:1585–92.PubMedCrossRef

46.

Schellens JHM. Capecitabine. Oncologist. 2007;12:152–5.PubMedCrossRef

47.

Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203–6.PubMed

48.

Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006;12:5491–5.PubMedCrossRef

49.

Deenen MJ, Tol J, Burylo AM, Doodeman VD, De Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17:3455–68.PubMedCrossRef

50.

Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899–902.PubMed

51.

Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res. 2004;10:2652–8.PubMedCrossRef

52.

Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, et al. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired ¹³CO₂ and plasma [2-13C]dihydrouracil. Clin Cancer Res. 2006;12:549–55.PubMedCrossRef

53.

Ishii Y, Suzuki S, Takahashi Y, Takayama T, Asai S. Can the 2-C-13-uracil breath test be used to predict the effect of the antitumor drug S-1? Cancer Chemother Pharmacol. 2010;66:333–43.PubMedCrossRef

54.

van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692–706.PubMedCrossRef

55.

Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997;57:3402–6.PubMed

56.

Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718–25.PubMedCrossRef

57.

Opdam FL, Dezentje VO, den Hartigh J, Modak AS, Vree R, Batman E, et al. The use of the (13)C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer Chemother Pharmacol. 2013;71(3):593–601.PubMedCrossRef

58.

Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, et al. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther. 2009;329:297–305.PubMedCrossRef

59.

Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J. 2005;5:365–73.PubMedCrossRef

60.

Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol. 2010;70:844–53.PubMedCrossRef

61.

US Food and Drug Administration. Drugs: genomics. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/default.htm. Accessed 20 Apr 2012.

62.

de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44:147–73.PubMedCrossRef

63.

Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85:155–63.PubMedCrossRef

64.

Breath test for women receiving tamoxifen in the prevention or treatment of breast cancer [ClinicalTrials.gov identifier NCT00873366]. http://www.clinicaltrials.gov/ct2/show/NCT00873366?term=breath+test&rank=3. Accessed 20 May 2013.

Title: Breath Tests to Phenotype Drug Disposition in Oncology
Authors: Frans L. Opdam
Anil S. Modak
Hans Gelderblom
Henk-Jan Guchelaar
Publication date: 01-11-2013
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 11/2013
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-013-0099-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Breath Tests to Phenotype Drug Disposition in Oncology

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2013

Pharmacokinetics and Pharmacodynamics of Anticoagulants in Paediatric Patients

Population Pharmacokinetics of JNJ-37822681, a Selective Fast-Dissociating Dopamine D2-Receptor Antagonist, in Healthy Subjects and Subjects with Schizophrenia and Dose Selection Based on Simulated D2-Receptor Occupancy

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus

Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs

Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1–31)NH2] in Postmenopausal Women with Osteoporosis